Resource Summary Report

Generated by dkNET on Sep 3, 2026

NCI-H2030

RRID:CVCL_1517
Type: Cell Line

Proper Citation

RRID:CVCL_1517

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1517

Proper Citation: RRID:CVCL_1517

Description: Cell line NCI-H2030 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: PMID:1311061, PMID:8806092, PMID:11030152, PMID:20164919, PMID:20215515, PMID:22460905, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29444439, PMID:29681454, PMID:30894373, PMID:31068700, PMID:31803961, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2030

Synonyms: H2030, H-2030, NCIH2030

Cross References: BTO:BTO_0006438, CLO:CLO_0008041, EFO:EFO_0002274, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5914, BioGRID_ORCS_Cell_line:534, BioSample:SAMN03471413, BioSample:SAMN10988239, cancercelllines:CVCL_1517, Cell_Model_Passport:SIDM00715, ChEMBL-

Cells:CHEMBL3308769, ChEMBL-Targets:CHEMBL1075530, Cosmic:722045, Cosmic:903611, Cosmic:1146897, Cosmic:1609520, Cosmic:1995553, Cosmic-CLP:722045, DepMap:ACH-000521, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:722045, GEO:GSM206483, GEO:GSM274747, GEO:GSM274748, GEO:GSM434332, GEO:GSM784272, GEO:GSM794344, GEO:GSM817097, GEO:GSM887397, GEO:GSM888475, GEO:GSM1374717, GEO:GSM1670208, IARC_TP53:21552, IGRhCellID:NCIH2030, LiGeA:CCLE_404, LINCS_LDP:LCL-1648, PharmacoDB:NCIH2030_1058_2019, PRIDE:PXD030304, Progenetix:CVCL_1517, PubChem_Cell_line:CVCL_1517, Wikidata:Q54907906

ID: CVCL_1517

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260829T234731+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2030.

No alerts have been found for NCI-H2030.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. Molecular cell, 86(8), 1546.

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. Cancer discovery, 16(1), 135.

Zhu G, et al. (2026) Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. Cell reports, 45(5), 117338.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene, 45(31), 3244.

He D, et al. (2026) Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. Journal of the National Cancer Center, 6(3), 286.

Hu Z, et al. (2026) Extracellular ATP-P2RY2 signaling drives intratumoral prostaglandin E2 accumulation and adaptive resistance to immunotherapy in solid tumors. Immunity, 59(7), 1928.

Jameson NM, et al. (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. Cancer research communications, 5(2), 240.

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. Cancer research, 85(1), 118.

Zhu T, et al. (2025) Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response. Molecular cell.

Liu C, et al. (2025) Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression. Cancer research, 85(13), 2429.

Pan K, et al. (2025) ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. The Journal of biological chemistry, 302(2), 111110.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(6), 1069.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Zhang Q, et al. (2025) PLK1-mediated PDHA1 phosphorylation drives mitochondrial dysfunction, mitophagy, and cancer progression in Cr(VI)-associated lung cancer. The Journal of biological chemistry, 301(7), 110406.

Maso L, et al. (2025) Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy. Nature communications, 16(1), 11264.

Pulawska-Moon K, et al. (2024) Novel ectopic expression of zona pellucida 3 glycoprotein in lung cancer promotes tumor growth. International journal of cancer.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

Thatikonda V, et al. (2024) Genetic dependencies associated with transcription factor activities in human cancer cell lines. Cell reports, 43(5), 114175.

Ye F, et al. (2023) TGF?? Antagonizes IFN??-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma. Cancer research, 83(13), 2262.

Cheung AH, et al. (2023) MLK4 promotes glucose metabolism in lung adenocarcinoma through CREB-mediated activation of phosphoenolpyruvate carboxykinase and is

regulated by KLF5. Oncogenesis, 12(1), 35.